Skip to main content

Yea Christopher's Form 4 filing

KalVista Pharmaceuticals, Inc. (KALV) · filed May 19, 2023

Accession no.
0001209191-23-031295
Filed
May 19, 2023
Trade date
Jan 11-May 18, 2023
Filing delay
128 daysLate
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 3 derivative transactions. Open-market sales total $26.4K. It was filed 128 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Yea ChristopherCIK 0001691102Officer (Chief Development Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 17, 2023Common StockMOption exerciseAcquired+4,205–F1–39,914Direct
May 18, 2023Common StockSSaleDisposed−2,604$10.14−$26,404.5637,310Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 11, 2023Common StockAGrant or awardAcquired+29,166$0.00$029,166Direct
May 17, 2023Common StockMOption exerciseDisposed−2,431$0.00$024,305Direct
May 17, 2023Common StockMOption exerciseDisposed−1,774$0.00$021,285Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)